Eli Lilly and Co (LLY) Actualités

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase...

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly to participate in Leerink Partners Global Healthcare Conference PR Newswire INDIANAPOLIS, Feb. 28, 2025...

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with...

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities